# IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

> **NCT03457649** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 62 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** ARGX-113
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03457649
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-09
- **Primary completion:** 2016-11-15
- **Final completion:** 2017-02-21
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457649, "IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03457649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*